Skip to Late-Breaking Abstracts »

Poster Presentation Dates

All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.

Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).

Search word or phrase:

# Title Authors Category Keywords
P517 Potent anti-tumor effect of systemically administered nanoparticles containing a TLR7 agonist in combination with radiotherapy Camilla Stavnsbjerg, MSc; Esben Christensen, MSc; Rasmus Münter, MSc; Andreas Kjær, MD, PhD; Svetlana Panina, MD, PhD; Martin Bak, PhD; Jonas R. Henriksen, PhD; Simon Jensen, PhD; Anders E. Hansen, DVM, PhD; Thomas L. Andresen, PhD; Combination Immunotherapies Antigen presenting cells; Immune adjuvant; Myeloid cells; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment
P671 Delivery of TLR7 agonists by Deep-Primed™ T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity Austin W. Boesch, PhD; Vasily Rybakin; Nathan Westcott; Ji Young Hwang; Kira Jørgensen; Rasmus Lassen; Martin Kraemer; Martin Bak, PhD; Gael Veiga; Jonas Bruun, PhD; Carlos Tassa; Harrison Rodts; Manny Sequeira; Glenn Leary; Santina Caruso; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Karsten Sauer, PhD; Thomas L. Andresen, PhD; Immune-stimulants and immune modulators Adoptive immunotherapy; Antigen presenting cells; Cytokine; Dendritic cell; Immune toxicity; MDSC; T cell; TLR; Tumor antigens; Tumor microenvironment
P676 Intratumoral delivery of TransCon™ TLR7/8 Agonist provides potent anti-tumor activity as a monotherapy and in combination with IL-2 while minimizing systemic cytokine induction Luis A. Zuniga, PhD; Torben Leßmann; Lars Holten-Andersen; Nicola Bisek; Joachim Zettler; Sebastian Stark; Frank Faltinger; Oliver Kracker; Samuel Weisbrod; Robin Müller; Tobias Voigt; Kornelia Bigott; Mohammad A. Tabrizifard; Vibeke Breinholt; Kennett Sprogøe; Juha Punnonen; Immune-stimulants and immune modulators Antigen presenting cells; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment
P756 HER2-targeting TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR- dependent manner. Shelley E. Ackerman, PhD; Joseph C. Gonzalez; Cecelia I. Pearson; Shelley E. Ackerman, PhD; Justin A. Kenkel; Po Y. Ho; Angela Luo; Murray N. Nguyen; Jason C. Paik, MD PhD; Arthur Lee; Richard P. Laura; Hai Li; Cindy Kreder; Karla A. Henning; Steve J. Chapin; Bruce H. Devens; Brian S. Safina; David Y. Jackson; Edgar Engleman; David Dornan, PhD; Michael N. Alonso; Novel Single-Agent Immunotherapies Antibody; Antigen presenting cells; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens